Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from RUA Life Sciences ( (GB:RUA) ).
RUA Life Sciences reported that activity in its UK contract development and manufacturing arm remains strong, with two main manufacturing contracts underpinning revenue and a growing pipeline of development work worth about £500,000 expected to be billed this financial year. Around 60% of these projects relate to approved or near-approved products, giving the company line of sight to potential manufacturing contracts exceeding £5 million annually and supporting management’s view that the business has reached a key growth inflection point.
The Abiss unit is currently trading below budget as a major customer runs down inventories, and RUA is negotiating an arrangement to align stock levels while securing two-year revenue visibility. Meanwhile, the biomaterials division is trading broadly in line with prior periods with further growth expected from a new Elast-Eon contract and potential royalty uplift, and the structural heart unit has signed Heads of Terms for third-party funding to advance pre-clinical development of a novel AurTex-based heart valve, reinforcing the value of the Group’s IP and partnerships.
The most recent analyst rating on (GB:RUA) stock is a Hold with a £13.50 price target. To see the full list of analyst forecasts on RUA Life Sciences stock, see the GB:RUA Stock Forecast page.
Spark’s Take on RUA Stock
According to Spark, TipRanks’ AI Analyst, RUA is a Neutral.
The score is primarily driven by solid top-line growth and a conservative balance sheet, but it is held back by weak profitability and negative operating cash flow. Technicals are supportive due to an established uptrend, yet the very high P/E meaningfully detracts from the overall rating.
To see Spark’s full report on RUA stock, click here.
More about RUA Life Sciences
RUA Life Sciences is a UK AIM-quoted medical device group specialising in implantable textiles and its proprietary biostable polymer Elast-Eon, supplying both contract development and manufacturing services as well as licensed biomaterials. The Group also owns France-based Abiss, a manufacturer of implantable devices, and is developing structural heart technologies including AurTex-based heart valve applications.
Average Trading Volume: 162,988
Technical Sentiment Signal: Sell
Current Market Cap: £8.07M
Find detailed analytics on RUA stock on TipRanks’ Stock Analysis page.